Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $10.83 and traded as low as $9.50. Astellas Pharma shares last traded at $9.67, with a volume of 96,545 shares traded.
Astellas Pharma Price Performance
The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39. The company has a market cap of $17.61 billion, a PE ratio of -44.23 and a beta of 0.34. The firm has a 50 day moving average of $9.61 and a two-hundred day moving average of $10.80.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last released its earnings results on Tuesday, February 4th. The company reported $0.30 EPS for the quarter. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. Research analysts predict that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.
About Astellas Pharma
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Read More
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
